Adverum Biotechnologies CEO and leadership

Laurent Fischer joined Tobira's Board of Directors in April 2009 and became Chief Executive Officer in 2014. Laurent Fischer brings 20 years of drug development and commercialization experience in the biopharmaceutical industry. Prior to joining Tobira full time he was Chairman and Chief Executive Officer of Jennerex Inc., a private, clinical-stage biotherapeutics company focused on the design, development and commercialization of first-in-class, breakthrough targeted oncolytic immunotherapy products for cancer that was sold for up to $150 million. Prior to Jennerex, he was co-founder, president and CEO of Ocera Therapeutics (NASDAQ: OCRX), where he licensed and developed OCR-002 the first ammonia scavenger for the treatment of complications of liver disease and oversaw the approval of Zysa®, the first treatment approved for irritable bowel syndrome in Europe. Laurent Fischer has co-founded and managed four healthcare companies and held senior management positions at DuPont-Merck, DuPont Pharmaceuticals, and Hoffmann-La Roche in liver disease, virology and oncology. Laurent Fischer was responsible for the global launch of Sustiva® the first once-daily anti-HIV therapy, now part of the fixed dose combination therapy Atripla® and was involved in the launch of Invirase®, the first protease inhibitor, in the United States. Laurent Fischer received his undergraduate degree from the University of Geneva and his medical degree from the Geneva Medical School, Switzerland.

Peter Soparkar is Adverum’s chief operating officer, responsible for leading the human resources, AD/QC/QA, clinical operations, legal, information technology, and facilities. Mr. Soparkar has 20 years of experience, including corporate development, corporate governance, legal, regulatory, commercial, and public compliance activities, for biotechnology companies as well as at a leading international law firm. Previously, Mr. Soparkar was chief legal officer and head of human resources at Counsyl, Inc., where he also served as corporate secretary and head of compliance. Earlier, Mr. Soparkar was at Jazz Pharmaceuticals for ten years, where he led the legal team’s support of company operations and other business matters, including delivering on numerous debt and equity financings and four landmark transactions. Earlier in his career, Mr. Soparkar worked at Latham & Watkins in London and San Francisco, with a practice spanning international and domestic markets, as well as private and public transactions. He earned a J.D. from New York University and a B.A. in economics and politics from Oberlin College.

Results-oriented executive skilled in leading finance, strategy and operations. Passion for guiding companies toward strategic and operational success. Top-tier private equity background. Well-versed in financing, fundraising, IPO and M&A transactions. Experienced in forming business strategies and managing multiple operational teams, including at healthcare technology startup scaling from 150 to 500+ employees. Successfully leading adoption of data analytics to drive revenue growth, pioneer key product features, and improve operations.

Aaron Osborne, MBBS MRCOphth is Adverum’s chief medical officer and joined the Company in April 2019. Dr. Osborne has over twelve years of experience in the biopharmaceutical industry together with five years of clinical practice in the British National Health Service (NHS) as an ophthalmologist. Dr. Osborne brings previous experience from Genentech, where he served as principal medical director in product development and global development leader for faricimab, guiding the design and execution of Phase II and Phase III studies in wet age-related macular degeneration (AMD) and diabetic macular edema (DME), respectively. Previously, Dr. Osborne served as global medical affairs pharmaceuticals franchise head at Alcon. He served as head of global medical affairs for ophthalmic programs at Novartis, where he led the medical oversight of Lucentis’ late-stage development and post-marketing studies, achieving worldwide regulatory approvals and patient access in wet AMD, DME, retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV). Dr. Osborne trained in ophthalmology at Queens Medical Centre, Nottingham, and earned his Bachelor of Medicine, Bachelor of Surgery (MBBS) degree at University College London.

Laurent Fischer joined Tobira's Board of Directors in April 2009 and became Chief Executive Officer in 2014. Laurent Fischer brings 20 years of drug development and commercialization experience in the biopharmaceutical industry. Prior to joining Tobira full time he was Chairman and Chief Executive Officer of Jennerex Inc., a private, clinical-stage biotherapeutics company focused on the design, development and commercialization of first-in-class, breakthrough targeted oncolytic immunotherapy products for cancer that was sold for up to $150 million. Prior to Jennerex, he was co-founder, president and CEO of Ocera Therapeutics (NASDAQ: OCRX), where he licensed and developed OCR-002 the first ammonia scavenger for the treatment of complications of liver disease and oversaw the approval of Zysa®, the first treatment approved for irritable bowel syndrome in Europe. Laurent Fischer has co-founded and managed four healthcare companies and held senior management positions at DuPont-Merck, DuPont Pharmaceuticals, and Hoffmann-La Roche in liver disease, virology and oncology. Laurent Fischer was responsible for the global launch of Sustiva® the first once-daily anti-HIV therapy, now part of the fixed dose combination therapy Atripla® and was involved in the launch of Invirase®, the first protease inhibitor, in the United States. Laurent Fischer received his undergraduate degree from the University of Geneva and his medical degree from the Geneva Medical School, Switzerland.

Mehdi Gasmi is a President and Chief Scientific Officer at ADVERUM BIOTECHNOLOGIES, INC..